Lundberg I, Hedfors E
Department of Rheumatology, Huddinge University Hospital, Sweden.
J Rheumatol. 1990 Oct;17(10):1340-5.
To analyze whether corticosteroids in low doses during limited time periods could be safely used in the treatment of patients with polymyalgia rheumatica (PMR) or temporal arteritis (TA) the records of 91 patients diagnosed between 1980 and 1987 were reviewed. The mean initial prednisolone dose was in patients with PMR 18 mg/day and the mean duration of treatment was 17 months. In patients with TA the mean initial dose was 31 mg/day and the mean duration of treatment 16 months, and in all the corticosteroid treatment was terminated within 24 months. Patients with coexisting TA and PMR demanded longer treatment compared to patients with either TA or PMR and thus 18/91 patients were treated for more than 2 years. No visual or neurological complications occurred after treatment with corticosteroids had been initiated. Our study indicates that most patients with PMR or TA can be treated safely with an initial prednisolone dose of 10 mg given twice daily. With few exceptions corticosteroid treatment can be terminated within 24 months.
为分析在有限时间段内低剂量皮质类固醇激素是否可安全用于治疗风湿性多肌痛（PMR）或颞动脉炎（TA）患者，我们回顾了1980年至1987年间确诊的91例患者的记录。PMR患者的泼尼松龙初始平均剂量为18毫克/天，平均治疗时长为17个月。TA患者的初始平均剂量为31毫克/天，平均治疗时长为16个月，所有患者的皮质类固醇激素治疗均在24个月内终止。与单纯TA或PMR患者相比，同时患有TA和PMR的患者需要更长时间的治疗，因此91例患者中有18例接受了超过2年的治疗。开始使用皮质类固醇激素治疗后未出现视力或神经并发症。我们的研究表明，大多数PMR或TA患者可以安全地接受初始剂量为每日两次、每次10毫克泼尼松龙的治疗。除少数例外情况外，皮质类固醇激素治疗可在24个月内终止。
